explore -WSS

explore

author：knowledge 2025-09-07 04:12:50 - browse：8874

This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy drug. — Novo Nordisk via AP

PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss.

The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or cardiovascular-related death — by 20%. That finding, which was the primary outcome the trial set out to study, was stronger than many were expecting and led Novo’s stock to surge.

But details of the study, including risk reductions for each specific heart complication, were not released until Saturday, when they were presented here — before a standing-room only crowd — as the first major session of the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： MD Anderson's Padmanee Sharma responds to research credit suit

WSS

Lack of health data on LGBTQ+ people has serious consequences

Surprise medical billing ban raises prices elsewhere

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Lack of health data on LGBTQ+ people has serious consequences

Florida health officials providing scant details on measles cases

explore

explore

knowledge

Medicare details structure of new drug price negotiation program

As AI regulations shape up, health tech startups beg for clarity

Bright Health sells Medicare Advantage business to Molina

$1 billion proposal to grow Boston, Massachusetts biotech

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Medicare details structure of new drug price negotiation program

As AI regulations shape up, health tech startups beg for clarity

Anesthesiologist group: stop taking Ozempic before surgery

Stem cell biologist probes earliest stages of human development

focus

Readout Newsletter: The latest on Novo Nordisk, Alnylam, Apogee

Pregnant women don't need prenatal multivitamins, study concludes

Fetal cell organoids grown from amniotic fluid, study finds

Reporting on presidential health from Reagan to Trump and Biden

Elevance, SCAN deals highlight health insurer acquisition scrutiny

Why Talkspace is targeting Medicare, a tricky market

leisure time

knowledge

focus

hotspot